ReViVox®
Rescue of complications from off-target muscle paralysis following botulinum toxin type A therapies (aesthetic & medical, e.g., overactive bladder)
Key Facts
About DelNova
DelNova is a private, pre-clinical biotech targeting a clear white space in the drug delivery market: the reversal of complications from botulinum neurotoxin therapies. The company leverages its drug delivery expertise to develop ReViVox®, a potential first-in-class rescue therapy for off-target paralysis in both aesthetic and medical (e.g., overactive bladder) applications. Operating in a market with no direct competitors, DelNova aims to improve patient quality of life and expand the safety profile of the widely used botulinum toxin procedure. Its success hinges on advancing its lead candidate through clinical development and securing regulatory approval.
View full company profile